A possible synergistic effect of Betahistine and Selegiline on the improvement of cochlear micorcirculation

Betahistine is widely applied for the conservative treatment of Menière’s Disease. However, mode of action and dosage are still matter of debate. Earlier studies in animals showed an increase of cochlear microcirculation with the application of 0.1 mg/kg b. w. or more. Selegiline is an inhibitor of Monoamine oxidases and thereby has the potential to increase the effect of Betahistine by slowing of its degradation. Therefore, this experimental study investigates joint systemic application of both agents.

Dunkin-Hartley guinea pigs were treated in general anesthesia in 3 experimental groups with 6 animals each. A small window was opened over the basal turn of the Cochlea to expose the Stria vascularis. FITC-dextran 0.1 g/kg b. w. was applied to contrast plasma from red blood cells. Cochlear blood flow was assessed by intravital microscopy before and after application of experimental agents. Animals received either Betahistin 0.01 mg/kg b. w. + Selegiline 1.0 mg/kg b. w., Placebo + Selegiline 1.0 mg/kg b. w. or Placebo + Placebo. Animals that received Betahistine + Selegiline showed a statistically significant increase in Cochlear blood flow. The effect was seen between 4 and 17 minutes from application of experimental agents, achieved an increase in blood flow from 126.8  ±  50.8  %  to 158.3  ±  38.7  %  (p  <  0.02 to p  <  0.001) and was reversible.

This suggests that Selegiline may further intensify the increasing effect of Betahistine on Cochlear blood flow. Future experimental investigations should clarify the underlying mechanism. Clinical trials that prove the benefit of Betahistine in Menière’s disease are still warranted.

Poster-PDF A-1588.pdf

Bundesministerium für Bildung und Forschung

Conflict of interest

Der Erstautor gibt keinen Interessenskonflikt an.

Publication History

Article published online:
13 May 2021